SCHEMBL492448

SCHEMBL492448

COc1cc(NS(=O)(=O)c2ccc(Cl)cc2)c(C(=O)Nc2ccc(S(=O)(=O)C3CCCNC3)cc2)cc1OC

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.53
GPR27 Q9NS67 3/20 0.48
AVPR2 P30518 1/20 0.48
SLC10A2 Q12908 1/20 0.47
SLC10A1 Q14973 1/20 0.47
SLC10A6 Q3KNW5 1/20 0.47
MAPK1 P28482 2/20 0.46
NPSR1 Q6W5P4 2/20 0.45
KMT2A Q03164 3/20 0.44
POLB P06746 1/20 0.44
HPGD P15428 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
RXFP1 Q9HBX9 1/20 0.44
KDM4E B2RXH2 3/20 0.43
MEN1 O00255 2/20 0.42
SLC20A2 Q08357 1/20 0.42
SLC20A1 Q8WUM9 1/20 0.42
LMNA P02545 1/20 0.42
TP53 P04637 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27576884 0.84 ALDH1A1 (0.49) ALDH1A1GPR27AVPR2SLC10A2SLC10A1
SCHEMBL492162 0.83 ALDH1A1 (0.62) ALDH1A1GPR27AVPR2SLC10A2SLC10A1
SCHEMBL491822 0.79 ALDH1A1 (0.59) ALDH1A1GPR27AVPR2SLC10A2SLC10A1
SCHEMBL491713 0.79 ALDH1A1 (0.67) ALDH1A1GPR27AVPR2SLC10A2SLC10A1
SCHEMBL492166 0.77 ALDH1A1 (0.58) ALDH1A1GPR27AVPR2SLC10A2SLC10A1
SCHEMBL491750 0.77 KMT2A (0.64) ALDH1A1GPR27AVPR2SLC10A2SLC10A1
SCHEMBL492394 0.77 ALDH1A1 (0.56) ALDH1A1GPR27AVPR2SLC10A2SLC10A1
SCHEMBL491974 0.77 ALDH1A1 (0.63) ALDH1A1GPR27AVPR2SLC10A2SLC10A1
SCHEMBL492332 0.76 ALDH1A1 (0.60) ALDH1A1GPR27AVPR2SLC10A2SLC10A1
SCHEMBL422152 0.76 ALDH1A1 (0.59) ALDH1A1GPR27AVPR2SLC10A2SLC10A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8541410-B2 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2013-09-24 US disclosed
US-20120108573-A1 SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM SANOFI-AVENTIS DEUTSCHLAND GMBH 2012-05-03 US disclosed
US-8106213-B2 For example, 2-(4-chloro-phenylsulfonylamino)-4,5-dimethoxy-N-(4-(thiomorpholine-4-sulfonyl)-phenyl)-benzamide; for therapy and prophylaxis of cardiovascular diseases such as hypertension, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2012-01-31 US disclosed
US-20080096936-A1 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them TELEVOX SOFTWARE, INCORPORATED 2008-04-24 US disclosed
US-7326789-B2 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2008-02-05 US disclosed
EP-1614678-A2 Sulfur substituted sulfonylaminocarboxylic acid N-heteroarylamides, their preparation, their use and pharmaceutical preparations comprising them Sanofi-Aventis Deutschland GmbH (DE) 2006-01-11 EP disclosed
EP-1095016-B1 SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM SANOFI AVENTIS DEUTSCHLAND (DE) 2005-11-09 EP disclosed
US-6881735-B2 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-04-19 US disclosed
US-20040186145-A1 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH. 2004-09-23 US disclosed
US-20020061887-A1 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them AVENTIS PHARMA DEUTSCHLAND GMBH 2002-05-23 US disclosed
US-6335334-B1 HYPERTENSIVE AGENTS, ANTICOAGULANTS; CARDIOVASCULAR AND SEXUAL DISORDERS, ANGINA PECTORIS, AND ATHEROSCLEROSIS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2002-01-01 US disclosed
EP-1095016-A1 SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM Aventis Pharma Deutschland GmbH (DE) 2001-05-02 EP disclosed
WO-2000002851-A1 SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2000-01-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108573-A1 SULFUR SUBSTITUTED SULFONYLAMINOCARBOXYLIC ACID N-ARYLAMIDES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL PREPARATIONS COMPRISING THEM GUCY1A1, GUCY1B1, GUCY1A2 ALDH1A1 457/4885GPR27 2636/4885AVPR2 2049/4885
US-20040186145-A1 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them GUCY1A1, GUCY1B1, GUCY1A2 ALDH1A1 860/4885GPR27 2176/4885AVPR2 3104/4885
US-20020061887-A1 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them GUCY1A1, GUCY1B1, GUCY1A2 ALDH1A1 860/4885GPR27 2176/4885AVPR2 3104/4885
US-20080096936-A1 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them GUCY1A1, GUCY1A2, GUCY1B1 ALDH1A1 391/4885GPR27 2632/4885AVPR2 1787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.